These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33126941)

  • 61. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
    Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
    Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
    Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Efficacy and Safety of Bedaquiline in the Treatment of Pulmonary Tuberculosis Patients: A Systematic Review and Meta-Analysis.
    Tong E; Wu Q; Chen Y; Liu Z; Zhang M; Zhu Y; Wu K; Pan J; Jiang J
    Antibiotics (Basel); 2023 Aug; 12(9):. PubMed ID: 37760686
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis.
    Rudolph D; Redinger N; Schwarz K; Li F; Hädrich G; Cohrs M; Dailey LA; Schaible UE; Feldmann C
    ACS Nano; 2023 May; 17(10):9478-9486. PubMed ID: 37160267
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE; D'Ambrosio L; Centis R; Tiberi S; Dheda K; Alffenaar JW; Amale R; Belilowski E; Bruchfeld J; Canneto B; Denholm J; Duarte R; Esmail A; Filippov A; Davies Forsman L; Gaga M; Ganatra S; Igorevna GA; Lazaro Mastrapa B; Manfrin V; Manga S; Maryandyshev A; Massard G; González Montaner P; Mullerpattan J; Palmero DJ; Pontarelli A; Papavasileiou A; Pontali E; Romero Leyet R; Spanevello A; Udwadia ZF; Viggiani P; Visca D; Sotgiu G; Migliori GB
    J Infect; 2019 Jan; 78(1):35-39. PubMed ID: 30096332
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB/HIV co-infected patients in KwaZulu-Natal, South Africa.
    Bionghi N; Daftary A; Maharaj B; Msibi Z; Amico KR; Friedland G; Orrell C; Padayatchi N; O'Donnell MR
    BMC Infect Dis; 2018 Apr; 18(1):171. PubMed ID: 29642874
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Guglielmetti L; Jaspard M; Le Dû D; Lachâtre M; Marigot-Outtandy D; Bernard C; Veziris N; Robert J; Yazdanpanah Y; Caumes E; Fréchet-Jachym M;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182570
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.